Book contents
- Club Drugs and Novel Psychoactive Substances
- Club Drugs and Novel Psychoactive Substances
- Copyright page
- Contents
- Acknowledgements
- Part I Introduction
- Part II Stimulant Drugs
- Part III Depressant Drugs
- Part IV Synthetic Cannabinoid Receptor Agonists
- Chapter 17 Synthetic Cannabinoid Receptor Agonists (SCRAs)
- Part V Hallucinogens
- References
- Index
Chapter 17 - Synthetic Cannabinoid Receptor Agonists (SCRAs)
from Part IV - Synthetic Cannabinoid Receptor Agonists
Published online by Cambridge University Press: 21 September 2020
Book contents
- Club Drugs and Novel Psychoactive Substances
- Club Drugs and Novel Psychoactive Substances
- Copyright page
- Contents
- Acknowledgements
- Part I Introduction
- Part II Stimulant Drugs
- Part III Depressant Drugs
- Part IV Synthetic Cannabinoid Receptor Agonists
- Chapter 17 Synthetic Cannabinoid Receptor Agonists (SCRAs)
- Part V Hallucinogens
- References
- Index
Summary
SCRAs were first developed for the illicit market to mimic the effects of natural cannabis and to appeal to natural cannabis users. However, despite this they have tended to be most commonly used by vulnerable groups, such as the homeless and prisoners, where their appeal appears to be that they are cheap and potent intoxicants.
Information
- Type
- Chapter
- Information
- Club Drugs and Novel Psychoactive SubstancesThe Clinician's Handbook, pp. 89 - 98Publisher: Cambridge University PressPrint publication year: 2020
Accessibility standard: Unknown
Accessibility compliance for the PDF of this book is currently unknown
and may be updated in the future.